In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Personalizing Patient Care:Sanofi Recasts Its Diabetes Efforts

Executive Summary

In a bid to protect its most valuable product, Lantus, Sanofi’s new diabetes division intends to provide holistic solutions in an effort to help patients better manage their disease. Will it work?
Advertisement

Related Content

Biopharmaceuticals Beyond The Drug: Changing Pharma's Value Proposition
Sanofi Reworks R&D To Tackle Risk, Meet Unmet Need
Medtech Venture Capital: The View From Europe
Endo Dives Deeper Into Devices With AMS Acquisition
A Look Back At 2010: In Search Of New Biopharma Models
Rising Payor Influence Means Successful Drug Launches are Rarer
Sanofi-AgaMatrix Deal a Harbinger
Pharma's Strategic Divide: Focus or Diversify
Novo Nordisk: Riding High on Diabetes
Novo Nordisk & The Challenge of Disease Management

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003531

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel